136 related articles for article (PubMed ID: 6576383)
41. [Contrast material with oxygenated Fluosol-DA, 20 for the protection against complications of catheter cerebral angiography].
Oda Y; Okumura T; Morimoto M; Murata T; Kamimura Y; Uchida Y; Mori K
No Shinkei Geka; 1984 Nov; 12(12):1369-77. PubMed ID: 6521827
[TBL] [Abstract][Full Text] [Related]
42. [Morphology of the pig liver after Fluosol infusion].
Petutschnigk D; Herrmann M; Hirlinger WK
Z Mikrosk Anat Forsch; 1980; 94(5):908-12. PubMed ID: 7210801
[TBL] [Abstract][Full Text] [Related]
43. [Suppression of infarctic changes with mannitol and fluorochemicals--an experimental study].
Tanaka S; Seki H; Yoshimoto T; Suzuki J
No To Shinkei; 1981 Nov; 33(11):1141-6. PubMed ID: 6800387
[TBL] [Abstract][Full Text] [Related]
44. Canadian Red Cross lecture. Current concepts of oxygen-transporting blood substitutes.
Bolin RB
Can J Surg; 1982 Jul; 25(4):422-4. PubMed ID: 7046893
[TBL] [Abstract][Full Text] [Related]
45. Liquid-gas partition coefficients of halothane and isoflurane in perfluorodecalin, fluosol-DA, and blood/fluosol-DA mixtures.
Tremper KK; Zaccari J; Cullen BF; Hufstedler SM
Anesth Analg; 1984 Jul; 63(7):690-2. PubMed ID: 6731898
[No Abstract] [Full Text] [Related]
46. Differential enhancement of melphalan cytotoxicity in tumor and normal tissue by Fluosol-DA and oxygen breathing.
Teicher BA; Holden SA; Rose CM
Int J Cancer; 1985 Nov; 36(5):585-9. PubMed ID: 3932225
[TBL] [Abstract][Full Text] [Related]
47. Lack of complications in long-term survivors after treatment with Fluosol and oxygen as an adjuvant to radiation therapy for high-grade brain tumors.
Evans RG; Kimler BF; Morantz RA; Batnitzky S
Int J Radiat Oncol Biol Phys; 1993 Jul; 26(4):649-52. PubMed ID: 8330996
[TBL] [Abstract][Full Text] [Related]
48. Use of a whole blood substitute, Fluosol-DA 20%, after massive postpartum hemorrhage.
Karn KE; Ogburn PL; Julian T; Cerra FB; Hammerschmidt DE; Vercellotti G
Obstet Gynecol; 1985 Jan; 65(1):127-30. PubMed ID: 3871250
[TBL] [Abstract][Full Text] [Related]
49. [Effect of fluosol-DA, an artificial blood, on the osmotic fragility of erythrocytes (author's transl)].
Nogami T; Tsuno K; Yamashiro K; Terasaki H
Masui; 1980 Nov; 29(12):1495-502. PubMed ID: 7463709
[No Abstract] [Full Text] [Related]
50. Influence of Fluosol-DA infusion on the complement activation and on the blood level of histamine in man.
Fukushima K; Nakamura M; Hinuma K
Prog Clin Biol Res; 1983; 122():291-8. PubMed ID: 6878373
[No Abstract] [Full Text] [Related]
51. Extracorporeal circulation with perfluorochemicals (Fluosol-DA).
Hoshino S; Iwaya F; Igari T; Kanno M; Honda K
J Cardiovasc Surg (Torino); 1982; 23(6):463-9. PubMed ID: 7153234
[TBL] [Abstract][Full Text] [Related]
52. Extended use of Fluosol emulsion in acute myocardial ischemia treatment.
Ohyanagi H; Saitoh Y; Uchida T; Watanabe M; Yamanouchi K; Yokoyama K; Mitsuno T
Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):941-9. PubMed ID: 1391538
[TBL] [Abstract][Full Text] [Related]
53. [Influences of Fluosol-DA infusion on the complement activation and on the blood level of histamine in man].
Fukushima K; Nakamura M; Hinuma K
Masui; 1983 Feb; 32(2):192-8. PubMed ID: 6854932
[No Abstract] [Full Text] [Related]
54. Success in the radical resection of esophageal cancer with artificial blood infusion: case report.
Mitsuno T; Kawa Y; Kita A; Kohno N
Int Surg; 1981; 66(4):355-8. PubMed ID: 7345051
[TBL] [Abstract][Full Text] [Related]
55. [Changes in cerebral and muscular gas tension during normo-volemic hemodilution with Fluosol-DA in dogs (author's transl)].
Kosugi I; Kitagaki T; Okada K; Matsushima K
Kokyu To Junkan; 1980 Apr; 28(4):389-94. PubMed ID: 7403706
[No Abstract] [Full Text] [Related]
56. [Indices of oxygen supply to the bodies of rats following blood replacement by a perfluorodecalin emulsion].
Chaplygina ZA; Kuznetsova IN; Domracheva VS; Gokhman NSh; Maksimov BN
Biull Eksp Biol Med; 1980 Nov; 90(11):546-8. PubMed ID: 6778535
[TBL] [Abstract][Full Text] [Related]
57. Effect of various oxygenation conditions and fluosol-DA on cancer chemotherapeutic agents.
Teicher BA; McIntosh-Lowe NL; Rose CM
Biomater Artif Cells Artif Organs; 1988; 16(1-3):533-46. PubMed ID: 2460166
[TBL] [Abstract][Full Text] [Related]
58. [Body's oxygen supply after total blood substitution with organofluoric emulsions].
Iarochkin VS; Koziner VB; Kolonina IR; Afonin NI
Gematol Transfuziol; 1983 Jul; 28(7):47-51. PubMed ID: 6618141
[No Abstract] [Full Text] [Related]
59. Rationale for the clinical studies of anemia treated with the perfluorochemical emulsion: Fluosol DA 20%.
Tremper KK
Prog Clin Biol Res; 1983; 122():307-13. PubMed ID: 6348785
[No Abstract] [Full Text] [Related]
60. Further studies on intake and retention of PFC substance of Fluosol-DA in RES in humans.
Mitsuno T; Tabuchi Y; Ohyanagi H; Sugiyama T
Prog Clin Biol Res; 1983; 122():257-63. PubMed ID: 6878368
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
